Sort   by:  
 Page size 
UnknownInhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer Progression.
Not available
S-EPMC5479329 | biostudies-literature
UnknownThe intracellular domains of the EphB6 and EphA10 receptor tyrosine pseudokinases function as dynamic signalling hubs.
Not available
S-EPMC8454701 | biostudies-literature
UnknownAcquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.
Not available
S-EPMC12593227 | biostudies-literature
UnknownTargeting homologous recombination deficiency in uterine leiomyosarcoma.
Not available
S-EPMC10157936 | biostudies-literature
UnknownMethylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Not available
S-EPMC6162272 | biostudies-literature
UnknownMitophagy in Intestinal Epithelial Cells Triggers Adaptive Immunity during Tumorigenesis.
Not available
S-EPMC6354256 | biostudies-literature
UnknownAge- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
Not available
S-EPMC5019754 | biostudies-literature
UnknownAntibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Not available
S-EPMC8927425 | biostudies-literature
UnknownNeutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903 | biostudies-literature
UnknownFactors associated with D-dimer levels in HIV-infected individuals.
Not available
S-EPMC3953205 | biostudies-literature
Sort   by:  
 Page size